Proactive Investors - Run By Investors For Investors

Shares of DiaMedica Therapeutics rise after its chronic kidney disease drug seen as safe, well-tolerated

The Minneapolis biotech says the interim results came from a Phase 1b study of 28 patients
kidney
Chronic kidney disease is a progressive condition leading to the gradual loss of kidney function over time

Shares of DiaMedica Therapeutics Inc (NASDAQ:DMAC) jumped Thursday after the biotech reported that its drug DM199 was observed to be safe and well-tolerated in patients with chronic kidney disease.

The Minneapolis, Minnesota-based company said the interim results came from a Phase 1b study of 28 patients with moderate and severe chronic kidney disease. The results were consistent with earlier DM199 studies in healthy volunteers.

Following the announcement, DiaMedica’s stock increased 38% to $5.28 a share on heavy volume.

READ: Investors cheer ContraVir's positive results from a human-liver experiment using its CRV431 drug candidate

“The initial clinical data supports the expected mechanism of action for DM199,” said Dr Harry Alcorn Jr, chief medical officer at DiaMedica. “Most importantly, we’re encouraged about DM199’s potential as a treatment option to improve the lives of patients with chronic kidney disease.”

Chronic kidney disease is a progressive condition leading to the gradual loss of kidney function over time. Early stages of CKD may be present with few or no signs or symptoms and the majority of patients do not know they have kidney disease. DM199 is designed to lower the progression of the disease.

DM199 is currently being studied in a Phase 2 clinical study for acute ischemic stroke and the company is preparing to initiate Phase II clinical studies in patients with chronic kidney disease.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full DMA profile View Profile

DiaMedica Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use